Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).

28 Jan 2010

GenSpera commences treatment in G-202 Phase I trial for solid tumors

GenSpera, Inc. announced that the first patient was treated in the Phase I clinical study of its cancer chemotherapeutic agent, G-202, at the University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. The trial is also being conducted at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

27 Jan 2010

Mayo Clinic achieves new levels of excellence in service to humanity

Mayo Clinic announced today that it raised $1.35 billion in its first comprehensive fundraising campaign, surpassing the goal of $1.25 billion.

27 Jan 2010

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations.

27 Jan 2010

Prostate cancer: Surgery in county hospitals, radiation or hormone therapy in private facilities

Researchers at Moores Cancer Center at the University of California, San Diego and colleagues have found that prostate cancer treatments varied significantly between county hospitals and private providers. Patients treated in county hospitals are more likely to undergo surgery while patients treated in private facilities tend to receive radiation or hormone therapy. These findings were published online by the journal Cancer on January 25.

25 Jan 2010

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced final data from a randomized, controlled Phase 2 trial of picoplatin in metastatic colorectal cancer (CRC) patients.

24 Jan 2010

NJHA honors professionals and organizations for sustainable healthcare

Several individuals and organizations were honored at the 91st Annual Meeting of the New Jersey Hospital Association today at the Hyatt Regency Princeton.

23 Jan 2010

IsoRay expands market awareness program by joining www.StockProfile.com

IsoRay, Inc., announced today that they have expanded their market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.

23 Jan 2010

AKD Global announces new class of cancer treatments in development

AKD Global announced today the discovery of a new class of cancer treatments in development, providing hope for millions of sufferers. The spectacular results demonstrate a highly potent effect on cancer cells with no toxicity to healthy tissue. AKD is raising funds to continue development.

22 Jan 2010

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.

22 Jan 2010

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

CPRIT awards the first $61M in grants for cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) awarded on January 20th the first $61 million in grants for cancer research projects at academic institutions and private companies throughout Texas. These are the inaugural grants of the $3 billion to be invested in cancer research in Texas over the next ten years.

21 Jan 2010

Medco Health Solutions launches Medco TRC for oncology patients

Medco Health Solutions, Inc. today announced the launch of the Medco Therapeutic Resource Center® (TRC) for oncology patients headquartered in Whitestown, Ind., where specialist pharmacists will manage the company's more than 850,000 patients currently living with cancer, one of the fastest growing segments of healthcare.

21 Jan 2010

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. have received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM® (lidocaine topical patch 5%).

20 Jan 2010

Research article addressing incidental findings in MRI-enterography in patients with CD to be published

MRI is increasingly used in the assessment of small bowel CD. Unlike conventional radiology, MRI enables visualization of disease extension beyond the intestinal wall, i.e., abscesses and fistulas. However, some extra-intestinal findings are unexpected and without relation to CD.

18 Jan 2010

Androgen replacement therapy may ward off heart damage, says study

A man's male hormones may ward off heart damage by helping vessels around the heart regenerate, suggest Australian researchers in a report posted January 13 in the Journal of Experimental Medicine (www.jem.org).

18 Jan 2010

New research shows cutting tobacco smoking reduces cancer deaths in Europe

New research on deaths from cancer in Europe concludes that the key priority for continuing to reduce mortality is cutting tobacco smoking. The study shows that, while deaths for men from lung cancer in the EU have declined overall, by 17 % from 1995 to 2004, they rose by 27% for women over the same period.

17 Jan 2010

Spectros expands T-Stat product line with new Continuum Cerebral Sensor

Spectros announced today that the T-Stat® Tissue Oximeter sensor line will be expanded to include the new Continuum™ Cerebral Sensor line upon receipt of FDA marketing approval anticipated in 2010.

13 Jan 2010

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds.

13 Jan 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Celgene reports total revenue of $758M for fourth-quarter of 2009

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

GenSpera commences treatment in G-202 Phase I trial for solid tumors

Mayo Clinic achieves new levels of excellence in service to humanity

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

Prostate cancer: Surgery in county hospitals, radiation or hormone therapy in private facilities

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

NJHA honors professionals and organizations for sustainable healthcare

IsoRay expands market awareness program by joining www.StockProfile.com

AKD Global announces new class of cancer treatments in development

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

CPRIT awards the first $61M in grants for cancer research

Medco Health Solutions launches Medco TRC for oncology patients

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Research article addressing incidental findings in MRI-enterography in patients with CD to be published

Androgen replacement therapy may ward off heart damage, says study

New research shows cutting tobacco smoking reduces cancer deaths in Europe

Spectros expands T-Stat product line with new Continuum Cerebral Sensor

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in